RBL Communications
  • Home
  • About
  • Services
  • Investment Hub
  • Contact
Select Page

RBL Investor Focus: Freegold Ventures Limited – Advancing High-Grade Gold at Alaska’s Golden Summit

Nov 11, 2024

Company Overview Freegold Ventures Limited (FVL), a Canadian exploration company, focuses primarily on gold projects within North America. Headquartered in Vancouver, British Columbia, Freegold’s flagship project, Golden Summit, is located near Fairbanks, Alaska,...

Nova Pacific Metals Initiates Call for Drill Bids on Proposed 8,000 Meter Drill Program at the Lara Project

Nov 8, 2024

Vancouver, British Columbia –  November 8, 2024 – Nova Pacific Metals Corp. (CSE: NVPC) (OTCQB: NVPCF) (FRA: YQ10) (WKN: A40GFH) (the “Company”, or “Nova Pacific”) is pleased to announce that planning is underway for a proposed 2025...

Kontrol Technologies Announces $2 Million Bitcoin Purchase Plan and Expanding with Data Center Customers

Nov 8, 2024

TORONTO – Kontrol Technologies Corp. (Cboe CA:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol” or the “Company”) operates a sustainable buildings platform for customers including REITS, municipalities, property managers and industrial and commercial buildings. Following...

Analyzing Eloro Resources’ Strategic Capital Raise: Investor Confidence and Growth Potential in the Iska Iska Project

Nov 1, 2024

Eloro Resources’ successful closing of a $3.78 million non-brokered private placement through the issuance of 4.2 million units is a strategic move aimed at bolstering its exploration efforts at the Iska Iska project in Bolivia. This influx of capital will facilitate...

PharmaDrug’s Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases

Oct 31, 2024

Toronto, Ontario – October 31, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as...

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Oct 31, 2024

TORONTO, Oct. 31, 2024 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical...
« Older Entries
Next Entries »

Follow Us

Categories

  • Al O'Grady
  • Anfield Energy
  • Blog
  • Boba Mint Holdings
  • Kontrol Energy
  • News
  • PharmaDrug
  • Revive
  • Uncategorized
  • Home
  • About
  • Services
  • Investment Hub
  • Contact
  • Facebook
  • X
© COPYRIGHT 2025. RBL Communications Inc. ALL RIGHTS RESERVED.